BillionToOne

BillionToOne develops diagnostic tests using single molecule sequencing technology. The company offers Prenatal Unity Complete®, a non-invasive prenatal test assessing fetal risk for recessive conditions and aneuploidy from maternal blood, and Northstar Select® and Northstar Response®, liquid biopsy tests for cancer therapy selection and treatment monitoring. Customers include healthcare providers serving pregnant patients and cancer patients.